Basedon this, the nonapeptide E75 (HER-2369–377, KIFGSLAFL)was identified, and it was shown that this can be recognized specificallyby CTL on ovarian tumors.114 A number ofother HER-2 peptides were preferentially recognized by one or twoCTL cell lines, indicating that both common and specific HER-2 epitopesmay show immunoactivity against ovarian tumors. Here, ERBB2 is linked to ovarian neoplasm.